Abstract
Introduction

40
Many bioactive agents present in foods (nutraceuticals) or drugs (pharmaceuticals) 41 intended for oral ingestion are highly lipophilic molecules with low and/or variable 42 bioavailability [1] [2] [3] [4] [5] [6] . The poor bioavailability characteristics of these bioactive agents may 43 be the result of a number of physicochemical or physiological processes: restricted 44 release from the product matrix 7 ; low solubility in gastrointestinal fluids 2, 8 ; low 45 permeability across intestinal epithelial cells 6, 9 ; and/or, enzymatic or chemical 46 transformations within the gastrointestinal tract (GIT) 3, 10, 11 . Research in the food, 47 nutrition, and pharmaceutical disciplines has established that the bioavailability of many 48 bioactive agents depends strongly on the nature of the foods ingested with them 2, 3, 5, 8, 49 12-16 . Both the composition and the structural organization of the food matrix may 50 influence the bioavailability of co-ingested bioactive agents 17 . The dependence of the 51 oral bioavailability of lipophilic bioactive agents on food matrix characteristics means 52 there is considerable opportunity for designing food-based delivery systems to improve 53 the efficacy of lipophilic pharmaceuticals and nutraceuticals. 54
Medical, Functional and Excipient Foods
55
There is increasing convergence in the interests of the pharmaceutical and food 56 industries in the development of products to prevent or treat human diseases (Figure 1) . 57
The pharmaceutical industry is developing drug preparations to combat chronic or acute 58 diseases, whereas the food industry is developing food and beverage products whose 59 purpose is to promote human health and wellbeing through diet. In particular, there is a 60 considerable overlap in the development of food-based approaches to improve the 61 bioavailability of lipophilic bioactive agents, such as nutraceuticals and pharmaceuticals. 62
These approaches are based on the design of the composition or structure of food 63 matrices to increase bioavailability and have led to new classes of foods: functional foods; 64 used excipients in the pharmaceutical industry include lipids, surfactants, synthetic 90 polymers, carbohydrates, proteins, cosolvents, and salts. By analogy, an excipient food 91 may not have any bioactivity itself, but it may increase the efficacy of any nutraceuticals 92 or pharmaceuticals that are co-ingested with it. Excipient foods are therefore meant to 93 be consumed with a conventional pharmaceutical dosage form (e.g., capsule, pill, or 94 syrup), a dietary supplement (e.g., capsule, pill, or syrup), or nutraceutical-rich food (e.g., 95
fruits, vegetables, nuts, seeds, grains, meat, fish, and some processed foods). It is likely 96 that different kinds of excipient foods will have to be designed for different types of 97 bioactive agents or delivery matrices. Some examples of excipient foods that could be 98 developed to increase the bioavailability of nutraceuticals in foods are shown in Table 1 . 99
For example, the bioaccessibility of carotenoids in a salad may be increased by 100
consuming it with a specifically designed salad dressing. This dressing may contain 101 various food components that increase the bioavailability of the nutraceuticals in the 102 salad: lipids that increase intestinal solubility; antioxidants that inhibit chemical 103 transformations; enzyme inhibitors that retard metabolism; permeation enhancers that 104 increase absorption; efflux inhibitors. Indeed, previous studies have shown that the 105 bioavailability of oil-soluble vitamins and carotenoids in salads can be increased by 106 consuming them with dressings containing some fat 14 , which supports the concept of 107 excipient foods. 108 
112
In principle, a wide variety of different food products could be used as excipients to 113 increase the bioactivity of lipophilic bioactives, such as beverages, yogurts, dressings, 114 desserts, sauces, soups, dips, spreads, candies, and baked goods. These excipient foods 115 need to be selected so that they are economic, convenient, desirable, and effective, and 116 that can be regularly incorporated into a daily diet. 117
In the remainder of this review, we initially consider the design of excipient foods, 118 then we highlight the main factors limiting the bioavailability of lipophilic bioactive 119 components, and then we discuss the impact of food matrix composition and structure on 120 bioavailability and how this leads to the concept of excipient foods and excipient food 121
Potential benefits of excipient foods 148
There are several potential benefits of developing excipient foods to increase the 149 bioavailability of nutraceuticals and drugs. The long-term consumption of low levels of 150 nutraceuticals may improve human performance, enhance wellbeing, or inhibit the onset 151 of chronic diseases, such as heart disease, diabetes, hypertension, and cancer 5 . This 152
would increase the quality of life of the general population and reduce the costs of health 153 care associated with treatment of these chronic diseases. At present, the bioavailability 154 of the nutraceuticals in many natural sources, such as fruits and vegetables, is relatively 155 low, and therefore their potential benefits on long-term human health are not being fully 156 realized 3 . In addition, it is well established that the oral bioavailability of many 157 lipophilic drugs is relatively low and variable, which reduces their efficacy and can lead 158 to undesirable side effects 2, 22 . The development of specially designed excipient foods 159 that enhance bioavailability and bioactivity may be able to overcome these problems. 160
Limitations of excipient foods 161
The development of successful excipient foods faces a number of technical, legal, 162 and commercial challenges. In particular, there are important differences in the ability 163 to prove the impact of excipient foods on the bioactivity of drugs and nutraceuticals. 164
Drugs can be administered in well-defined doses at specified times thereby enabling 165 pharmaceutical researchers to carry out studies to establish their efficacy against specific 166 disease symptoms or biomarkers. Thus the impact of excipient foods on drug 167 bioactivity can be established using well-controlled experiments that involve taking the 168 drug in the absence or presence of the excipient food. In contrast, nutraceuticals are 169 typically consumed at relatively low levels as part of a complex diet over extended 170 periods. Hence, it is often difficult to establish a strong correlation between the type and 171 amount of nutraceutical consumed and a particular disease. This would make it 172 challenging to prove the efficacy of excipient foods at improving human health and 173 wellness since long-term studies would be needed with well-controlled diets. 174
Consequently, it would be difficult for food manufacturers to provide the scientific 175 evidence required by regulators to make specific health claims about an excipient food 176 product in their advertising or labeling. In the absence of this kind of competitive 177 advantage food companies may be reluctant to spend research funds on developing and 178 testing the efficacy of excipient foods. Nevertheless, one might be able to make the 179 simpler claim that excipient foods increase the bioavailability of specific food 180 components, such as carotenoids or oil-soluble vitamins. Another unique challenge that 181 the food industry faces is in controlling the dose and timing that a nutraceutical 182 containing food and an excipient food are consumed. Pharmaceuticals are usually 183 taken in well-defined doses at specific times, whereas nutraceutical agents may be 184 present in various types of foods that are consumed in different amounts by different 185 individuals as part of a complex diet that contains other components that could affect 186 bioavailability. The time that an excipient food is consumed relative to a 187 nutraceutical-rich food may also be important for the efficacy in enhancing bioavailability, 188 
Bioavailability of lipophilic bioactive agents
215
It is useful to highlight the major factors limiting the bioavailability of lipophilic 216 bioactive agents since this information will aid in the successful development of 217 efficacious excipient foods. The oral bioavailability of an ingested bioactive component 218 depends on the fraction that reaches the target site-of-action in a biologically active form 219 5 . The overall bioavailability (F) of a lipophilic bioactive component depends on 220 numerous factors (Figure 3 ) 24, 25 : 221
F L is the fraction of bioactive agent liberated from its original environment, which 223 may be a drug preparation or a food matrix, into the GIT so that it becomes bioaccessible 224 i.e., in a form suitable for absorption (F L 
Liberation 242
A lipophilic bioactive agent must be liberated from a food matrix (e.g., fruit, 243 vegetable, fish, meat, processed food) or drug preparation (e.g., pill or capsule) and then 244 solubilized within mixed micelles in the small intestinal fluids before it becomes 245 accessible for absorption (Figure 3) . Mixed micelles are assembled from bile salts and 246 phospholipids secreted by the body, as well as any lipid digestion products such as 247 monoacylglycerols and free fatty acids. It should be stressed that the expression "mixed 248 micelles" actually refers to a compositionally, structurally, and dynamically complex 249 mixture within the GIT that may contain various colloidal structures, such as micelles, 250 vesicles, and liquid crystals that changes over time during the digestion and absorption 251 metabolism often depends on the route that the bioactive agents are transported into the 276 systemic circulation 22, 34 . Strongly hydrophobic agents tend to be transported via the 277 lymphatic route, whereas less hydrophobic agents tend to be transported via the portal 278 vein and liver 33 . Lipophilic bioactives may be highly metabolized when they pass 279 through the liver before reaching the systemic circulation, thereby altering their 280 biological activity. In some cases, molecular transformations increase bioactivity, 281 whereas in other cases they decrease it. The transformation of a lipophilic bioactive as it 282 travels through the GIT and human body determine the fraction that arrives at the site of 283 action in a metabolically active state (F M ). The ability to alter the absorption pathway 284 of bioactive agents by manipulating dietary composition or structure provides an 285 important way of increasing the bioavailability of certain bioactives. 286
Distribution 287
After a lipophilic bioactive agent has been absorbed it is usually distributed amongst 288 various tissues within the human body (Figure 3) , such as the systemic circulation, liver, 289 kidney, muscles, adipose tissue, heart, lungs, brain, etc.
35 . The distribution of the 290 bioactive agent depends on the molecular characteristics of the bioactive, as well as those 291 of any co-ingested food components. The target tissue(s) for a bioactive agent depends 292 on the nature of the biological response required, such as enhanced performance, 293 maintenance of general wellbeing, prevention of chronic disease, or treatment of specific 294 acute diseases. 295
Excretion 296
Lipophilic bioactives and there metabolites are eventually removed from the human 297 body through a variety of mechanisms, and often end up within the feces, urine, sweat, or 298 breath 36 . It may therefore be possible to increase the bioavailability of an ingested 299 bioactive by increasing its persistence within the human body. The rate of excretion 300 determines the fraction of bioactive agent that remains at the site of action (F E ) at a 301 particular time. 302
Improving oral bioavailability 303
The oral bioavailability of ingested lipophilic agents can be improved by designing 304 excipient foods that increase the fraction liberated (F L ), absorbed (F A ), and reaching the 305 site of action (F D ) in a metabolically active form (F M ). This goal can be achieved by 306 manipulating the composition and structure of food matrices based on knowledge of the 307 impact of specific food matrix properties on the biological fate of ingested lipophilic 308 bioactives (see Section 5). 309
Impact of food matrix on bioavailability
310
The oral bioavailability of lipophilic bioactives in drugs or foods may be increased 311 by ingesting them with excipient foods with specifically designed compositions and 312 structures. In this section, some of the major ways in which food components may alter 313 the oral bioavailability of lipophilic bioactive agents is highlighted. It is assumed that 314 an excipient food should be fabricated entirely from food-grade ingredients that are 315 generally recognized as safe (GRAS). An excipient food could then be marketed and 316 distributed as a conventional food product with additional health benefits. 317
Potential mechanisms of action 318
The components within an excipient food may alter the oral bioavailability of 319 co-ingested lipophilic bioactives through various physicochemical or biochemical 320 mechanisms, which are highlighted in this section. 321
Bioactive liberation 322
Prior to ingestion, lipophilic bioactive agents are typically trapped within some kind 323 of fluid, semi-solid, or solid matrix in pharmaceutical or drug products. For example, a 324 lipophilic drug may be present within a pill or capsule, whereas a lipophilic nutraceutical 325 may be trapped inside the cells of a fruit or vegetable or within the fat droplets in a 326 processed food. The bioactive agents must therefore be liberated from their original 327 location before they can be solubilized within intestinal fluids and absorbed by the body 328 (Figure 3 ). An excipient food may therefore be designed so that it contains specific 329 ingredients that facilitate the release and solubilization of bioactive agents. The design 330 of this type of food requires knowledge of the physicochemical and physiological 331 processes that occur within the human gastrointestinal tract after ingestion (Figure 4) . 332
Release from Food or Drug Matrix 333
The breakdown of the matrix surrounding a bioactive agent within the human GIT is 334 usually carried out by mechanical, chemical, and enzymatic means [37] [38] [39] . Foods are 335 usually masticated within the mouth to break them down into smaller fragments prior to 336 swallowing, whereas pharmaceutical preparations (such as capsules and pills) are usually 337 swallowed directly. After swallowing, pharmaceutical or drug matrices may be broken 338 down in the stomach and small intestine due to the mechanical motions of the GIT, e.g., 339 peristalsis or grinding 38, 40, 41 . The high acidity and ionic strength of the stomach also 340 facilitates the dissociation of certain structures, particularly those held together by 341 electrostatic interactions 39, 42 . Some matrix dissociation may also occur due to the 342 simple fact that the material is dissolved within an aqueous environment, e.g., pills, 343 capsules, or powders formed from water-soluble substances such as carbohydrates or 344
proteins. The activity of digestive enzymes (such as amylases, proteases, and lipases) 345 stimulates the breakdown of major food components (such as starches, proteins, and 346 lipids), which often play an important role in maintaining the matrix structure in foods 347 and drug preparations. Secreted biological surfactants in the GIT, such as bile salts and 348 phospholipids, may also facilitate the breakdown of matrix structures held together by 349 
Alteration of Mass Transport Processes 387
The liberation of lipophilic bioactive agents within the GIT often depends on the 388 mass transport of reactants, catalysts, and products from one location to another. 389
Digestive enzymes must come into close proximity to their substrates before they can 390 carry out their catalytic actions. Bioactive agents solubilized within mixed micelles 391 must be transported through the lumen and across the mucous layer before they can be 392 absorbed by epithelial cells (Figure 5 ). The rate and extent of liberation of bioactive 393 agents from food or drug matrices may therefore be controlled by incorporating food 394 ingredients within excipient foods that alter mass transport processes within the lumen of 395 the GIT. In general, mass transport may occur by convective or diffusive processes, 396 depending on the structural and physicochemical properties of the intestinal fluids and the 397 flow profile within the region of the GIT involved 49 . The mechanical forces generated 398 by the GIT mix components together and help move them from one location to another 40, 399 50 . Nevertheless, there are regions within the GIT where mass transport is primarily 400 diffusion-limited, e.g., the movement of small molecules through gelled phases. 401 Excipient food components may be able to alter diffusion-limited or convection-limited 402 processes by various mechanisms: binding to bioactive agents; altering the microscopic 403 or macroscopic rheology of the intestinal fluids; altering GIT motility. For example, 404 some biopolymers are able to form viscous solutions or gels under simulated 405 gastrointestinal conditions, and may therefore be able to alter mass transport and transit 406 times, which in turn alter important events affecting the release and processing of 407 bioactive agents 51, 52 . Cationic biopolymers, such as chitosan, are able to bind anionic 408 bile salts and free fatty acids, and therefore alter their mass transport 53, 54 . 409 In other cases, an increase in gastric retention may decrease bioavailability, e.g., if the 424 transformed form has a lower bioavailability than the original form, or if some of 425 components released from the food matrix inhibit the subsequent solubilization or 426 absorption of the bioactive agents. Furthermore, an increase in the gastric emptying time 427 also slows down the rate at which bioactive agents are transported to small intestine, 428 which may have a significant impact on their absorption and metabolism in the small 429 intestine. 430
Alterations in Gut Motility
Bioactive absorption 431
There are numerous physicochemical and physiological mechanisms by which food 432 matrix components could alter the absorption of co-ingested lipophilic bioactive agents. 433 A number of the most important mechanisms that might be used in the development of 434 excipient foods are highlighted in this section. 435 ("tight junctions") that separate neighboring epithelial cells (Figure 5) typically occurs by an "endocytosis" mechanism 61 . In this case, particles come into 479 contact with the outer wall of the cell membrane, the membrane then wraps itself around 480 the particle, and then part of the membrane buds-off to form a vesicle-like structure with 481 a particle trapped inside that moves into the interior of the cell. This process may occur 482 in enterocyte cells, but is typically much more active in M-cells. The critical cut-off 483 particle size for endocytosis has been estimated to be from less than 50 to around 100 nm 484 for enterocyte cells, and to be from 20 to 500 nm for M-cells. 
Increase in membrane permeability
Inhibition of efflux mechanisms 496
The bioavailability of certain types of lipophilic bioactive agents is limited due to the 497 presence of efflux mechanisms in the membranes of the intestinal epithelial cells 57, 74, 75 . 498
After absorption by epithelial cells, some bioactives are transported back into the 499 intestinal lumen by specific transports at the apical side of the cell membrane. For 500 example, both P-glycoprotein (P-gp) and multidrug resistant protein (MRP) have been 501
shown to pump out a wide range of lipophilic bioactives from epithelial cells lining the 502 GIT 57, 74 . This efflux process can reduce the bioavailability of bioactive agents by two 503 mechanisms: (i) decreasing the total amount absorbed; and, (ii) increasing the extent of 504 metabolism within the GIT if the bioactive is pumped out and then reabsorbed, which 505 increase exposure of the bioactive to metabolizing enzymes inside of the epithelial cells. 506
Certain types of food-grade components have been shown to be able to block efflux 507 mechanisms, and thereby increase the net absorption of lipophilic bioactive agents by 508 epithelial cells, e.g., some surfactants, chelating agents, biopolymers, and phytochemicals 509 5, 57, 76, 77 . For example, resveratrol, quercetin and piperine have been shown to act as 510 efflux inhibitors for certain kinds of drugs 76, [78] [79] [80] [81] . In general, three different 511 mechanisms have been proposed for the ability of these components to inhibit efflux 512 processes: (i) blocking binding sites on the efflux protein surfaces; (ii) interference with 513 ATP hydrolysis (which provides the energy needed for efflux protein action); (iii) 514 alteration of cell membrane structure (which leads to alterations in efflux protein 515 conformation and activity) 57 . 516
Bioactive metabolism or chemical transformation 517
Numerous molecules isolated from plant and animal sources have been shown to 518 enhance the bioavailability of nutraceuticals or pharmaceuticals due to their ability to 519 interfere with chemical transformations that normally occur within the GIT or after 520 absorption 32 . Some of these bioactivity enhancers act as antioxidants that retard the 521 oxidation of nutraceuticals or pharmaceuticals, such as ω-3 fatty acids, carotenoids, or 522 conjugated linoleic acid 82 . For example, there are many natural and synthetic 523 food-grade antioxidants that are effective at inhibiting oxidation reactions by mechanisms 524 such as free radical scavenging, singlet oxygen quenchers, and chelating agents, e.g., 525
BHT, BHA, carotenoids, tocopherols, flavonoids, and grade seed extract 83 . Other 526 bioactivity enhancers may inhibit the normal functioning of metabolic or digestive 527 enzymes within the GIT or body 23, 32 . For example, piperine has been shown to retard 528 the metabolism of certain drugs and nutraceuticals, such as ibuprofen, curcumin, 529 resveratrol, EGCG, carotenoids, vitamins, and amino acids 32 . These affects have been 530 partly attributed to its ability to inhibit metabolizing enzymes such as glucose 531 dehydrogenase, cytochrome P450, and others 32 . 532 
Excipient food ingredients 538
In this section, the potential influence of common food components that may be 539 incorporated into excipient foods on the oral bioavailability of lipophilic bioactive agents 540 is discussed. Those ingredients that appreciably increase the bioavailability of 541 nutraceuticals can be referred to as "excipient food ingredients". An excipient food may 542 contain one or more of these ingredients so as to increase the bioavailability of one or 543 more nutraceuticals. 544
Lipids 545
Studies by pharmaceutical researchers have shown that co-ingestion of lipophilic 546 drugs with lipids improves theirs oral bioavailability by an amount that depends on the 547 amount, type, and structure of the ingested lipids 2 . Food and nutrition research has also 548 shown that the bioavailability of lipophilic nutraceuticals can be increased by 549 co-ingestion with lipids [85] [86] [87] . In vitro studies have reported that the bioaccessibility 550 (micelle solubilization) and absorption (cell culture uptake) of lipophilic bioactive agents 551 from fruits and vegetables is greatly increased in the presence of lipids 85, 86 . The extent 552 of the increase in bioaccessibility and absorption depends on the amount and composition 553 of the lipids used 86, 88, 89 . Bioaccessibility was higher for lipids containing long chain 554 triglycerides (LCT) than those containing short or medium chain triglycerides (SCT or 555 MCT), presumably because of differences in the solubilization capacity of the mixed 556 micelles formed 2, 90 . Lipophilic bioactives encapsulated within indigestible oils (flavor 557 oils) have been shown to have low bioaccessibility using in vitro studies, which was 558 attributed to the fact that some of them remained in the undigested oil droplets and there 559 were fewer mixed micelles available to solubilize them 90, 91 . In addition to their 560 composition, the liberation of bioactives from emulsified lipids also depends on their 561 particle size, physical state, and interfacial characteristics 92, 93 . Typically, the release 562 rate is faster for smaller particles, for liquid oils rather than solid fats, and for interfaces 563 where bile salts and lipases can easily absorb. 564
Co-ingested lipids may also alter the bioavailability of lipophilic drugs or 565 nutraceuticals through other mechanisms. When lipophilic bioactives are ingested with 566 LCT they are packed into lipoprotein particles (chylomicrons) in the intestinal epithelial 567 cells and then transported by the lymphatic route (thereby avoiding first pass metabolism 568 in the liver), but when they are ingested with SCT or MCT they tend to be transported via 569 the portal vein (where they must pass through the liver before entering the systemic blood 570 circulation) 34, 94 . Bioactives packaged in different vehicles (e.g, chylomicron vs. 571 non-chylomicron) in the epithelial cells may have different metabolic fates due to 572 differences in their exposure to metabolizing enzymes present in different body tissues. 573
Carbohydrates 574
In general, food carbohydrates are classified as monosaccharides (n = 1), 575 oligosaccharides (n = 2 to 20), or polysaccharides (n > 20) depending on the number of 576 monomers present 95 . Carbohydrates may also be classified as digestible or indigestible 577 depending on their susceptibility to enzymatic hydrolysis in the upper GIT 96, 97 . Starch 578 is the most abundant digestible polysaccharide in foods, whereas there are many types of 579 indigestible polysaccharides, such as cellulose, hemicellulose, pectin, alginate, 580 carrageenan, xanthan gum, locust bean gum, and agar. Indigestible polysaccharides are 581 part of a class of polymers known as dietary fibers, which vary according to their 582 monomer type, distribution, and bonding, as well as their electrical charge, 583 hydrophobicity, molecular weight, degree of branching, and conformation 95, 97 . 584
Co-ingested carbohydrates may influence the bioavailability of lipophilic bioactive drugs 585 and nutraceuticals through various mechanisms. As mentioned earlier, many 586 polysaccharides are able to increase the viscosity or form a gel within the GIT, thereby 587 altering mass transport processes, e.g., diffusion of enzymes to substrates in food 588 matrices, or digestion products/bioactives to epithelial cells. Some dietary fibers may be 589 
Excipient food ingredients 681
Many of the food ingredients discussed in the previous sections have the ability to 682 increase the oral bioavailability of co-ingested bioactive agents. These ingredients can 683 therefore be used to construct excipient foods that are specifically designed to increase 684 the overall oral bioavailability of one or more type of co-ingested bioactive agents. For 685 example, an excipient food may contain lipids to increase the solubilization capacity of 686 the intestinal fluids, a phytochemical to inhibit efflux mechanisms, and a surfactant to 687 increase epithelium cell membrane permeability. 688
Conclusions
689
This article has introduced the concept of excipient foods that are specifically 690 designed to enhance the oral bioavailability of lipophilic bioactive agents such as 691 nutraceuticals in foods or drugs in pharmaceuticals. Knowledge of the influence of 692 specific food components and structures on the bioavailability of specific lipophilic 693 bioactive agents is increasing, which will facilitate the rational design of food matrices 694 that can enhance the biological activity of nutraceuticals and drugs. A number of 695 different approaches can be used, including increasing the release, solubilization, 696 transport, and uptake of bioactive agents, while decreasing their metabolism or efflux. 697
There is a growing convergence in the interests of pharmaceutical and food 698 companies. The food industry is increasingly focusing on the development of functional 699 food and beverage products designed to improve performance, maintain wellbeing, and 700 inhibit the onset of chronic diseases, such as osteoporosis, heart disease, cancer,hypertension, and obesity. The pharmaceutical industry continues to develop products 702 to prevent, manage, and cure chronic and acute diseases. Many of the biologically 703 active substances present in foods and drugs are highly lipophilic agents that normally 704 have poor oral bioavailability. The availability of a range of excipient foods specifically 705 designed to increase the oral bioavailability of lipophilic bioactive molecules would 706 therefore be beneficial to both the pharmaceutical and food industries. Nevertheless, 707 further research is required to better understand the role of specific excipient food 708 ingredients on the bioavailability of specific lipophilic bioactive agents, and to establish 709 the influence of ingredient interactions on bioavailability when excipient foods are 710 consumed as part of a complex diet that contains many other components. 711 712 
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Figure 1: There is increasing convergence between the interests of the food and pharmaceutical industries in the development of products to prevent or treat diseases, particularly in the area of functional, medical, and excipient foods.
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Medical Food: A food or beverage product containing a drug to prevent or treat a specific disease. Functional Food: A food or beverage product containing a nutraceutical with health benefits over and above normal nutritional function. Excipient Food: A food or beverage product containing ingredients or structures that increase the bioavailability of drugs or nutraceuticals that it is consumed with. The oral bioavailability of a lipophilic bioactive agent depends on various liberation, absorption, distribution, metabolism, and excretion processes. Some of the key processes involved are shown schematically.
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